BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the underwriters of its recent public offering of its common stock have exercised in full their option to purchase an additional 600,000 shares. The total gross proceeds from this offering to BioCryst, including from the exercise of the over-allotment option, are expected to be $20.2 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioCryst. BioCryst expects to use net proceeds of this offering for general corporate purposes, including funding clinical development of BCX4161, continued development of second generation hereditary angioedema compounds and pre-commercialization activities related to intravenous peramivir. The offering, including the sale of the additional shares, is expected to close on August 6, 2013, subject to customary closing conditions.
Wells Fargo Securities, LLC and JMP Securities LLC acted as joint book-running managers, and Noble Financial Capital Markets acted as co-manager for the offering.
The shares of common stock described above are being offered by BioCryst pursuant to a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. A final prospectus supplement related to the offering was filed with the SEC and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Wells Fargo Securities, LLC, 1525 West W.T. Harris Boulevard, NC0675, Charlotte, NC 28262, Attn: Capital Markets Client Support, telephone: 1-800-326-5897 or email: firstname.lastname@example.org; or JMP Securities LLC, Attn: Prospectus Department, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, telephone: 1-415-835-8985.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts